Table 1 Stage I-III breast cancers by receptor-based subtype and proportion ILC, SEER 17 registries, 2010–2021
All subtypes | HR+/HER2− | HR+/HER2 + | TNBC | HR-/HER2+ | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total (N) | Total (N) | Total (%)* | ILC (N) | ILC (%)** | Total (N) | Total (%)* | ILC (N) | ILC (%)** | Total (N) | Total (%)* | ILC (N) | ILC (%)** | Total (N) | Total (%)* | ILC (N) | ILC (%)** | |
All diagnoses | 660,451 | 486,031 | 73.6 | 60,532 | 12.5 | 78,885 | 11.9 | 4016 | 5.1 | 67,624 | 10.2 | 940 | 1.4 | 27,911 | 4.2 | 312 | 1.1 |
N2-3M0(Any T) | 43,360 | 28,585 | 65.9 | 5533 | 19.4 | 6223 | 14.4 | 348 | 5.6 | 5785 | 13.3 | 179 | 3.1 | 2767 | 6.4 | 57 | 2.1 |
T3-4N0-1M0 | 38,742 | 23,307 | 60.2 | 6371 | 27.3 | 5898 | 15.2 | 463 | 7.9 | 6293 | 16.2 | 131 | 2.1 | 3244 | 8.4 | 66 | 2.0 |
